000 | 01926 a2200529 4500 | ||
---|---|---|---|
005 | 20250517100200.0 | ||
264 | 0 | _c20171219 | |
008 | 201712s 0 0 eng d | ||
022 | _a1473-5571 | ||
024 | 7 |
_a10.1097/QAD.0000000000001098 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSterling, Timothy R | |
245 | 0 | 0 |
_aThree months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. _h[electronic resource] |
260 |
_bAIDS (London, England) _c06 2016 |
||
300 |
_a1607-15 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAmericas |
650 | 0 | 4 |
_aAntitubercular Agents _xadministration & dosage |
650 | 0 | 4 | _aAsia |
650 | 0 | 4 | _aChild |
650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHIV Infections _xcomplications |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIsoniazid _xadministration & dosage |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aRifampin _xadministration & dosage |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTuberculosis _xcomplications |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aScott, Nigel A | |
700 | 1 | _aMiro, Jose M | |
700 | 1 | _aCalvet, Guilherme | |
700 | 1 | _aLa Rosa, Alberto | |
700 | 1 | _aInfante, Rosa | |
700 | 1 | _aChen, Michael P | |
700 | 1 | _aBenator, Debra A | |
700 | 1 | _aGordin, Fred | |
700 | 1 | _aBenson, Constance A | |
700 | 1 | _aChaisson, Richard E | |
700 | 1 | _aVillarino, M Elsa | |
773 | 0 |
_tAIDS (London, England) _gvol. 30 _gno. 10 _gp. 1607-15 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAD.0000000000001098 _zAvailable from publisher's website |
999 |
_c26075595 _d26075595 |